Merck has signed a licensing agreement worth up to $3.3 billion with Shanghai-based LaNova Medicines to develop, make and ...

Are you a print subscriber? Activate your account. By Garett Sloane - 2 hours 35 min ago By Gillian Follett - 2 hours 35 min ago By E.J. Schultz - 2 hours 35 min ago By Jack Neff - 2 hours 35 min ...

Explore listed products List your instruments Listings of Structured Products can be done with one days’ notice. Once an approved issuer, the review of the instrument application process is fast.

We do our very best to research and vet every product we recommend in our buying ... Those that earn top marks make our list of recommendations; moreover, these evaluations also help us rank ...

While it costs money to own a pet under all circumstances, some unexpected expenses can catch owners unawares and put them in ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Anyone crafting a bull case for the pharmaceutical giant Merck (NYSE: MRK) should include Keytruda as the company's best asset. The cancer drug has been Merck's top-selling medicine and its ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions.

Merck & Co was founded in 1970 and operates in Rahway, United States. The company engages in the sector 'Pharmaceuticals, Medicinal Chemical & Botanical Products' (ISIC: 2100). This industry ...